Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE.


Introduction
Systemic lupus erythematosus (SLE) is a chronic multisystem systemic inflammatory disorder characterized by an overactivated innate immune response, uncontrolled autoantibody production, and the presence of self-antigens that induce the deposition of immune complexes (1,2).Endogenous self-antigen and nucleosomes from apoptotic cells in SLE will activate plasmacytoid dendritic cells (DCs) through the Toll-like receptor (TLR) 7 and TLR 9 to interact with pathogenic self-reactive T cells for type 1 interferon production, and with B cells for the manufacture of autoantibodies (2)(3)(4)(5).The inappropriate stimulation of Th1 and Th17 inflammatory cytokines and the loss of self-tolerance will contribute to immune dysfunction and tissue inflammation in SLE (1,6,7).As shown in Figure 1, we summarize the pathogenesis of SLE in the overactivation of Th1 and Th17 responses with lower regulatory T cells (Tregs) resulting in a high expression of type 1 interferon cytokines and adhesion molecules that increase neutrophil netosis and tissue damage and apoptosis with nuclear DNA exposure for the induction of anti-DNA autoantibodies.Skewed lower Treg cells attributed to inappropriate immune homeostasis and proper targeting of imbalanced Treg function and/or low-dose IL-2 the administration could rescue the progress of SLE.
Tregs are vital for maintaining immune self-tolerance and regulation of immune tolerance by inhibiting autoimmune and inflammatory responses (8)(9)(10)(11).Natural CD4+ Tregs (nTregs) are derived from thymic precursors, consisting of approximately 5% to 10% of the circulating population of CD4+ T cells (12,13).The nTregs had high expression of CD25 and low expression of CD127 in CD4+ T cells, and the transcription factor forkhead box P3 (FoxP3) served as the best known Treg hallmarks (12,14,15).It is important to note that genetic factors contribute to the risk of developing SLE and immune dysregulation (16).Certain genes involved in T-cell activation, regulation, and type I interferons have been identified as risk factors for SLE susceptibility (17).For example, variations in the FoxP3 gene, which encodes the critical transcription factor for Treg development and function, have been linked to impaired Treg function in SLE patients.FoxP3 induces the expression of IL-2, CD25, CTLA-4, and miR-155 in Tregs (18).GDF7, a secreted ligand of the TGF-b superfamily of proteins, exhibited positive regulatory effects on Tregs via increasing the expression of FoxP3 and CTLA4.Recent research showed that the downregulation of GDF7 in CD4+ T cells could lead to impaired suppressive functions of lupus Tregs (17,19).Natural CD4+ Tregs are rendered unstable by loss of FoxP3 expression, which can ultimately lead to autoimmunity.FoxP3 mutation has been reported as a rare X-linked recessive (IPEX) syndrome with aggressive autoimmunity with the clinical feature of immune dysregulation, polyendocrinopathy, and enteropathy in humans (9,20).Epigenetic modifications, which can be influenced by both genetic and environmental factors, also impact T-cell function in SLE.The interaction between genetics, T cell abnormalities, and environmental factors also plays a critical role in in the onset and exacerbation of the disease (16).Natural Tregs-mediated immune regulation is mediated primarily by cell contact and suppressive cytokines (Table 1A).The immunoregulatory mechanism of nTregs includes the secretion of inhibitory cytokines with IL-10, IL35, TGF-b, and cell-contact inhibition with perforin and granzyme B, and the competition of IL-2 with effector T cell growth, and suppression of DC function (8).The tolerance of DCs can be induced by Tregs through positive feedback loops to reinforce the suppressive environment, and CTLA-4 expressed by Tregs can inhibit the expression of CD80 and CD86 on DCs to down-regulate effector T cells via the costimulatory cell surface protein CD28.Tolerogenic DCs can express inhibitory molecules such as indoleamine 2,3-dioxygenase (IDO) and retinoic acid, to improve Treg survival and proliferation to suppress autoimmunity (21).

Imbalance of immune regulatory cells in SLE
Numerical and functional deficits of abnormalities in Treg subtypes have been reported to have a significant impact on the pathogenesis and outcome from patients with autoimmune disorders (22)(23)(24)(25)(26). Elucidation of the roles of various subsets of Treg (Table 1) dedicated to immune balance will provide a novel therapeutic approach that governs immune tolerance for SLE remission (27,28).However, no definitive phenotypic markers or functions have been recognized to distinguish between these Treg subtype populations in SLE.In this mini-review, we summarize the current literature on the function and diversity of Treg subsets, focusing mainly on CD4+ Tregs, CD8+ Tregs, B regulatory cells, and type 1 regulatory T cells (Tr1), which provide immunotherapeutic modulation of SLE (Table 2).Furthermore, we discuss the clinical trials and therapeutic potential of regulatory cell-based therapies and lower-dose IL-2 therapy to restore immune tolerance by Tregs manipulation in patients with SLE.

Natural regulatory T cells in SLE
Controversial results were reported whether decreased and increased Tregs cells frequencies were reported in SLE.This discrepancy may arise from the difference in phenotypic analyses and the composition of study cohorts.Control groups in clinical trials are made up of patients who receive a standardized treatment or placebo.The baseline characteristics and ongoing treatments of these patients can affect Treg populations.For example, high-dose glucocorticoid therapy has been found to increase the percentage of circulating Tregs in active lupus patients (61).Although circulating CD4+Treg levels have concluded inconsistent results, there is increasing evidence to specify that the numbers of CD4+Tregs were substantially reduced in patients with lupus (Table 2A).A meta-analysis showed that a lower percentage of Tregs/CD4+T cells was observed in patients with active lupus compared to those with inactive SLE (31).A recent meta-analysis showed that SLE patients had a decreased Treg/PBMC ratio, which Treg is defined by CD4 +CD25+, CD4+FoxP3+ and CD4+CD25+FoxP3+ compared to healthy subjects.However, no significant differences were found between the percentage of CD4+Tregs and the activity of SLE  disease due to the sample size or inclusion criteria (29).Another meta-analysis showed that patients with active SLE have a decreased absolute number of CD4+Tregs and the results were not affected by the gating strategies (30).However, considering that most patients with lupus received glucocorticoid, CD4+Treg has been reported to be unaffected by drug therapy (62).Furthermore, lupus patients have an increased rate of CD4+ Tregs apoptosis and a decrease in total Tregs count, and CD4+Tregs apoptosis which was positively associated with lupus disease activity (63).Th17 cells play a critical role in the pathogenesis of SLE and several evidences have confirmed that refining the balance of CD4+Treg/Th17 cells could benefit from reducing disease activity (32,64).The disturbance between Th17 and CD4+Treg proliferation was highlighted by an imbalance in FoxP3 and RORgt gene expression in the development of SLE (6).Dysregulated Th17/CD4+ Treg cell balance was associated with miR-19b gene expression.Exosomes from human umbilical cord blood-derived mesenchymal stem cells could regulate the expression of inflammatory factors through in vitro miR-19b/KLF13 experiments in patients with lupus (32) (Table 2A).In lupus murine models, CD4+Foxp3+ Treg cells reduced the suppressive capacity against T cell proliferation, and adoptive transfer of Treg cells leads to lupus disease suppression and remission (33).Administration of recombinant IL-2 could restore the imbalance of effector T cells and proliferation of Treg cells (34, 35) (Table 2A).The T follicular helper cells (TFh), which are defined by a phenotype of Bcl6+CXCR5 high PD-1 high , in the germinal center had the ability to stimulate the follicular B cells for the production of high-affinity autoantibodies.Several studies discovered an increase in the number of peripheral TFh cells in lupus patients, which is positively correlated with disease activity and autoantibody titers (65).Circulating lymphoid tissue follicular Treg cells (TFr), which expressed PD-1, ICOS, CD25 and CXCR5, can suppress TFh cell activity by inhibiting IL-10, IL-35, and TGF-b cytokine production (66).An increase in circulating TFr cell numbers was observed with successful treatments in patients with SLE, suggesting that restoring TFr cells may provide new therapeutic methods in SLE (38) (Table 2B).In lupus murine models, the percentage of Tfh cells increased and the Tfr (CD4+CXCR5+FoxP3+) cells decreased in 16-week-old MRL/lpr mice (39) (Table 2B).
The disruption of CD4+Treg cell homeostasis triggered by the lack of IL-2 is a critical event in the pathogenesis of SLE (67).The number and function of CD4+Treg can be controlled by the IL-2/ STAT5 signaling pathway with sustained expression of FoxP3.IL-2 has also been reported to increase TFr proliferation which is dependent on the STAT5/Blimp-1 dependent mechanism (68).Impaired CD4+CXCR5+CD45RA-FoxP3 high TFr cells with defective IL-2 production could be found in patients with SLE (69).Furthermore, T cells from SLE patients exhibit abnormal microRNAs (for example, miR-200a-3p) and enzymatic activity of protein phosphatase 2A (PP2A), resulting in downregulation of IL-2 by inactivation of the phosphorylated cAMP response elementbinding protein (pCREB) (16, 70).
Loss of homeostatic balance is observed in lupus patients and restored human CD8+ Treg cells can be vital for the development of therapies in SLE (77).A decrease in circulating CD8+ FoxP3+ Treg cells has been observed in SLE patients, and autologous hemopoietic stem cell transplantation could increase CD8+Treg cells, which are related to better control (42).High-dose methylprednisolone therapy could increase circulating CD8+CD25+FoxP3+Tregs and decrease disease activity in patients with lupus nephritis (40).Alltrans retinoic acid has been shown to increase the CD4+ and CD8+ regulatory T Cells, which have therapeutic potential in the treatment of SLE and other autoimmune diseases (78) Furthermore, a nucleosomal histone peptide could improve human CD8+CD25+FoxP3+ T cells to decrease the production of pathogenic autoantibody via TGF-b/ALK-5/pSmad 2/3 signaling pathway (41) (Table 2C).

Regulatory B cells in SLE
SLE is associated with abnormal activation of B lymphocytes and excessive autoantibodies production.Regulatory B (Breg) cells have an important role in the maintenance of immune tolerance and attenuating systemic inflammation (47).Human Bregs are generally recognized to have a phenotype of CD24 high CD27+ or CD19+CD24 high CD38 high (52,53).Human B10 cells, which constitute approximately 25% of B cells in the blood, are activated by the B-cell receptor (BCR) of progenitor B10 cells (79,80).B10 cells as a functional Bregs subtype have a negative immunoregulatory function, and CD40 and CD40L signaling, apoptotic cells, and TLR signaling were able to increase the number of B10 cells (53, 80, 81).pDCs can induce Breg differentiation via an IFN-r-dependent pattern by secreting IL-10 and IL-35 (49, 51) (Table 1C).
Emerging evidence has revealed that Breg numerical deficiency and/or dysfunction play a critical role in the pathogenesis of lupus and other autoimmune diseases (47,82,83).Identification and characterization of Bregs facilitate new approaches to targeting pathogenic B cells in patients with SLE (84) (Table 2D).Impaired regulatory B cells producing granzyme B were found in patients with SLE (82).Patients with lupus nephritis had a significantly decreased in circulating IL-10+ Bregs levels compared to health controls (51).Patients with new-onset lupus nephritis had a decrease in CD19+CD5+CD1d high IL-10+ Bregs and restored Breg deficiency in patients who respond to immunosuppressive medications (48).The percentage of peripheral CD19 +CD24 high CD27+ B cells with IL-10 and IL-35 production was low in patients with new-onset SLE (47,52).Granzyme Bproducing Bregs, which play a negative regulatory role in immunity, and Granzyme B-producing B cell frequencies decreased in patients with SLE (82).During CD40 stimulation, decreased CD19+CD24 high CD38 high B cells with IL-10 production and inhibitory capacity was observed in SLE patients (85).pDCs initiative the differentiation of CD19+CD24 high CD38 high (immature) B cells into IL-10-producing CD24+CD38 high Breg cells.Defective pDC-mediated expansion of CD24+CD38 high Breg cells was associated with decreased activation of the STAT1 and STAT3 signaling pathway in patients with SLE.STAT1-STAT3 activation between pDC and CD24+CD38 high Breg cell interaction was restored in SLE patients responding to rituximab, a chimeric monoclonal antibody targeted against the CD20 marker (50).
Bregs and T cells can influence each other on the functions through direct cell-cell interactions and the production of cytokines.Dysfunctional Bregs may provide inadequate regulatory signals to T cells, leading to unchecked pro-inflammatory responses.Bregs exert profound impacts on the differentiation, function, and distribution of Tfh cells in the immune microenvironment.Human Breg cells control IL-21 receptor expressions in Tfh cell maturation, and inhibit Tfh cell-mediated antibody secretion through IL-10 and TGF-b (86).Human CD19+CD25 high Bregs can inhibit the expansion and function of autologous CD4+ T cells, and promote Treg differentiation and activity by secreting IL-10 ( 87).The IL-10independent regulatory mechanisms of Bregs to inhibit effector T cell differentiation are primarily mediated by IL-35, TGF-b, and granzyme B (88).Programmed death-ligand 1 high (PD-L1 hi ) Bregs inhibit Tfh cell expansion through elevated expression of PD-L1 (89).Furthermore, specific IgG4 antibodies produced by human CD73−CD25+CD71+IL-10-producing regulatory B cells could suppress antigen-specific CD4+ T cell proliferation (90).Enhancing Breg function or adoptive transfer of Bregs in animal models of SLE has shown promising results in reducing disease severity and ameliorating T-cell abnormalities.The development and function of Bregs are likely to be regulated by Tfh cells, and the percentage of B10 cells in the spleens had a positive correlation with Tfh cell-derived IL-21 from a MRL/lpr mice model (54).IL-17 deficiency led to an increased number of CD19+IL-10+Breg in the spleen of a murine model of lupus (55).The gut microbiota DNA has been shown to expand the Bregs in a murine lupus model (56) (Table 2D).Collectively, all these data support the fact that Breg cells are critical in T cells homoeostasis to ensure central tolerance and prevent autoantibodies production, and may have implications for the regulation of autoimmune diseases.
Tr1-like cells play a crucial role in suppressing antibody-driven immune responses.The function with inhibition of IgG production from Tr1-like cells was deficiency in SLE patients (57) (Table 2E).CD46, the complement regulatory protein, will be expressed in activated immune cells to prevent autologous complementmediated lysis of cells by binding to complement components C3b and C4b in an inflammatory situation (59, 96).The uncontrolled immune response of Th1 contributes to a wide range of lupus, and CD46 activation has emerged as a powerful controller of T cell-mediated immunity to contraction of Th1 immunity (59).Activation of CD46 proteins with IL-2 in activated CD4+ T cells will enhance the secretion of IL-10 and granzyme B, a phenotype shared with Tr1 cells (60, 96, 97) (Table 1E).Costimulation by CD3/CD46 proteins leads to IL-2 dependent Tr1-like cells with high IL-10 and low IFN-g level production, which is associated with disease activity in lupus patients (59, 98).Furthermore, we observed that the functional defect of IL-10+ Tr1-like cells in pediatric patients with lupus nephritis can be restored by corticosteroid treatment (58) (Table 2F).

Therapeutic potential of regulatory cells in SLE 3.1 Targeted-Treg therapies
Regulatory cell-based therapy can restore the homeostatic balance in the immune system (3,99,100).A variety of target regulatory cell-based therapies are currently being explored for SLE (Table 3).Conventional immunotherapy for SLE is mainly based on corticosteroids or/and immunosuppressive therapy (66,77,108).Restoration and maintenance of the Treg cell population have the therapeutic potential to improve immune tolerance by manipulating suppressive Tregs in patients with SLE (109-111).High-dose corticosteroid pulse therapy has been shown to induce monocytes to produce TGF-b and improve Treg differentiation.Furthermore, steroids play a role in activating Tregs through the miR-342-3p-mTOR complex 2 axis (22, 40, 101, 112) (Table 3A).Furthermore, antigen-specific Tregs can be triggered and expanded by administering autologous tolerogenic DCs with autoantigenic peptides and can be considered as a type of Treg therapies targeted against autoimmunity (22,27) (Table 3B).
Several studies have also investigated the mammalian target-ofrapamycin (mTOR) signaling pathway in Tregs and its impact on SLE pathogenesis (102).Rapamycin alone or in combination with all-trans retinoic acid reduced disease activity and the glucocorticoid requirement, which can regulate the balance of Th17/Treg cells (102, 103) (Table 3C).The tolerance of histone peptide was shown to be a novel therapy suitable for the treatment of lupus nephritis and restored Th17/Treg cell balance (64).Potent Treg cells are activated by histone peptide epitopes in vitro from patients with lupus, which can inhibit interferon and anti-dsDNA autoantibody production (41, 73, 104) (Table 3D).Treg therapy can be further enhanced by administering antigen-specific nanoparticles, or engineering Treg cells to be autoantigen-specific T cell receptor (TCR) or chimeric antigen receptor (CAR)-specific Tregs (22,105) (Table 3E).

Low-dose IL-2 therapy on the balance of Tregs
CD25 is persistently expressed in CD4+ FoxP3+ Tregs, when IL-2 activated CD25 forming high affinity IL-2R to compete for available IL-2 in the circulation (113).The decrease in IL-2 level was found to be associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus (114,115).High doses administration of recombinant human IL-2 (rIL-2) can aid conventional T cells and naïve CD8+ T cells that produce perforin, granzymes, IL-5, IL-13, and IFN-g (116).However, low-dose rIL-2 management preferentially promoted Treg cell-mediated beneficial activities in disease manifestations (105,106).
The benefit of low-dose IL-2 therapy was associated with restored Tfr/Tfh cell balance.In CD4+ T cells, IL-2 can directly activate Blimp-1 and suppress Bcl-6 to antagonize Tfh cell differentiation (106).Furthermore, IL-2 therapy also directly prevents the expression of RORgt, thereby repressing Th17 development, which plays a vital role in the development of autoimmune disorders (107) (Table 3F).Tfr cells from SLE patients had reduced suppressive function.PD-1+ Tfr cells in SLE were positively correlated with disease activity and anti-DNA antibody levels.With in vitro low-dose IL-2 stimulation, the expression of PD-1 in Tfr cells decreased significantly, together with the increased expression of CTLA-4 and FoxP3 (36).Low-dose IL-2 therapy increases the circulating Tfr/Tfh ratio, which was accompanied by reduced anti-dsDNA titers and improved kidney damage in mice and lupus patients (117).A randomized cohort study showed that patients with lupus who received prolonged lowdose IL-2 therapy recoveed the immune balance Tfr/Tfh in lupus (65, 118).

Summary of IL-2 clinical trials for SLE
Humrich et al. (119) first reported that a 36-year-old patient with SLE who received human IL-2 recombinant (aldesleukin) 1.5 or 3.0 million IU subcutaneous injections daily for five days can improve arthritis and the increase of CD25+FoxP3+CD127 lo Treg cells.Clinical and preclinical studies demonstrate that low-dose rIL-2 can be administered safely to humans and the potential benefits in the induction of remission in active lupus patients as shown in Table 4.The low-dose recombinant human rIL-2 regimens contain 3-4 cycles of 7-10 million IU and are separated by rest periods of 9-16 days (37,118,(120)(121)(122)(123)(124).Recent two randomized trials have shown that low-dose IL-2 therapy can restore the Treg population in active lupus patients.A randomized, double-blind, placebo-controlled clinical trial was designed to treat active lupus patients who received IL-2 at a dose of 1 million IU or placebo with standard treatment for 3 months and were followed for another 3 months.In the IL-2 group, the SRI-4 response rates were 55.17% compared to 30.00% in the control group.Although the SRI-4 response did not achieve a significant difference at 3 months, the IL-2 group had significantly high SRI-4 response rate after 6 months follow-up.In the IL-2 group, patients with lupus nephritis had a complete remission rate of 53.85% compared to 16.67% in the placebo group.No obvious systemic side effect was observed in the IL-2 group.Low-dose IL-2 therapy can expand regulatory T cells and also maintain cellular immunity with improved natural killer cells (118).An international, multicenter, double-blind, randomized, placebocontrolled phase II clinical trial (LUPIL-2) to enroll hundred

Regimens
Effects/Mechanism References (68, 106, 107)  numbers was detectable in the responding patients, suggesting that the clinical outcome is associated with the increased Treg response (120).These results provide strong support for further testing of lower-dose IL-2 therapy in patients with SLE.
There are new modified forms of IL-2 which exhibit an extended half-life or a higher affinity for trimeric IL-2R in clinical trials (125).IL-2 mutein NKTR-358 with an extended half-life between 7 and 13 days had clinical effects on skin lupus and increased the number and percentage of CD25 hi Tregs in a randomized, placebo-controlled phase 1 trial (121).Low-dose IL-2 therapy has been associated with improved lupus disease activity, reduced autoantibody production, and the steroid-sparing effect.The ongoing research is focuses on further understanding the mechanism of low-dose IL-2 therapy, optimizing dosing protocols, and identifying specific patient subgroups that may benefit the most from this treatment approach.Furthermore, long-term safety and efficacy data from large-scale clinical trials are needed to establish the role of low-dose IL-2 therapy as an alternative regimen for SLE (118).In summary, clinical studies have consistently demonstrated that low-dose IL-2 therapy in SLE is well tolerated, and capable of increasing suppressive Treg population that appears to provide complementary immunomodulatory effects on the treatment of SLE.

Concluding remarks
Elucidation of the roles of various subsets of Treg dedicated to immune homeostasis and the restoration of the balance between Tregs and autoreactive T cells will provide a novel therapeutic potential that governs immune tolerance for the remission of SLE.Although more data on the manipulation and propagation of Tregs subsets and their therapeutic application are still needed, promising clinical responses were observed in patients with SLE who received low-dose IL-2 therapy to balancing Th17 versus Tregs.Future research is warranted to decipher new immunotherapeutics of the balance between Th1/Th17 overactivation and the development of nTregs and peripheral Tregs in SLE.

1
FIGURE 1 Schematic diagram showing the pathogenic mechanism of overactivated T cell responses and the therapeutic potential of regulatory cells with lowdose IL-2 therapy in systemic lupus erythematosus.(A) SLE is characterized by increased apoptosis and defective clearance mechanisms leading to the formation of immune complexes against the self-antigen.These immune complexes cause neutrophil netosis and activate plasmacytoid dendritic cells to interact with self-reactive pathogenic T cells.(B) Overactivation of Th1 and Th17 responses results in high expression of type 1 interferon, cytokines, and adhesion molecules that increase tissue damage and induction of anti-DNA autoantibodies.(C) Subsets of skewed lower Treg cells with inappropriate immune homeostasis will contribute to the worsening of lupus.(D) IL-2 induces Tregs differentiation in association with STAT5 phosphorylation with sustained expression of FoxP3.IL-2 directly inhibits expression of RORgt and blocks Th17 development.IL-2 also induces Blimp-1 to decrease Bcl-6 expression in T follicular helper cells.Low dose IL-2 therapy restores Treg suppressive function mainly by secreting inhibitory cytokines with IL-10, TGF-b, IL-35, and cytolysis with granzyme B and perforin, and deprivation of effector T cell growth with IL-2 and suppression of dendritic cell function.(created with BioRender.com).Agreement number: QI25RDVKPZ.
induces CD4+ T cell apoptosis, which promotes monocytes to produce TGF-b and further facilitates Treg differentiation.Steroids induce Tregs through miR-342-3p-mTOR complex 2 axis.anti-inflammatory cytokines, secrete retinoic acid, and indoleamine 2,3-dioxygenase (IDO), both of which enhance Treg survival and proliferation. of the rapamycin inhibitor (mTOR) and retinoic acid expands Tregs and maintains suppressive function.and anti-DNA-based peptides (pConsensus) expansion CD4+ and CD8+ Tregs and suppress CD4+ T cells and B cell proliferation.specific nanoparticles to Tregs and engineering the Tregs to be autoantigen-specific T cell receptor (TCR) or chimeric antigen receptor (CAR) Tregs can be directly inhibited in self-reactive cells.A nucleosomal histone peptide induces human CD8+CD25+FoxP3+ T cells to suppress pathogenic autoantibody production by TGF-b/ALK-STAT5 phosphorylation with sustained expression of FoxP3.IL-2 directly inhibits RORgt and induces Blimp-1 to decrease Bcl-6 expression.

TABLE 1
The immune mechanism of human regulatory T cell subsets and regulatory B cells.

TABLE 2
Characteristics and main findings of regulatory T cell subsets and regulatory B cells in systemic lupus erythematosus.
Adoptive transfer of Treg cells leads to disease suppression and remission.Administration of recombinant recombinant IL-2 could restore the imbalance of effector T cells and proliferation of Treg cells.Tfr cells from patients with SLE had impaired suppressive function.PD-1+ Tfr cells in SLE positively correlated with anti-DNA antibody levels and disease activity.highTfrcells could be attributed to defective IL-2 production in patients with SLE.An increase in circulating Tfrs numbers was observed with successful treatments in patients with SLE.A nucleosomal histone peptide induces CD8+CD25+FoxP3+ T cells suppressed pathogenic autoantibody production by TGF-b/ALK-5/pSmad 2/3 signaling.+ CD24 high CD27 + B population with IL-35 decreased in active SLE patients, and correlated with disease activity.(47) (Continued) Tsai et al. 10.3389/fimmu.2023.1230264Frontiers in Immunology frontiersin.org

TABLE 3
Target regulatory cell-based therapies for systemic lupus erythematosus.

TABLE 4
Summary of clinical trials with low-dose IL-2 therapy in systemic lupus erythematosus.Primary end point: SRI-4 response at week 24 (IL-2: 65.5%, placebo: 36.7%;p=0.03), higher lupus nephritis remission rate, increase complement, reduction in anti-DNA antibodies in the IL-2 group.No SAE, increase in Treg cells in the IL-2 group.Higher remission rate in the IL-2 group at 10 weeks, improved renal outcomes.No SAE.Increase in Treg cells during cycles.Improvement in SLEDAI after 6,12 and 24 weeks.No SAE Increase in Treg cells during cycles.Reduced Th17 cell/Treg-cell ratio.Improvement in SLEDAI on day 62, increase in complement, reduction in anti-DNA antibodies.No SAE.Increase in circulating Treg cells and reduction in circulating B cells., standard of care treatment; SRI-4, SLE Responder Index-4; SAE, serious adverse event. SOC